Quanterix Extends Oncology Footprint with Accelerated Launch of Next Gen SP-X™ Platform and CorPlex™ Validated 10-Plex

Following successful beta program, the Simoa SP-X next
generation benchtop and CorPlex are launching ahead of schedule to
further revolutionize cancer research, immunotherapy monitoring, and
drug development

LEXINGTON, Mass.–(BUSINESS WIRE)–Quanterix
Corporation (NASDAQ:QTRX)
, a company digitizing biomarker analysis
with the goal of advancing the science of precision health, today
announced the much-anticipated full launch of its Simoa SP-X Imaging and
Detection System, 10-Plex Simoa CorPlex Cytokine Panel, and broad menu
of additional multiplex panels. The new instrument platform and highly
validated CorPlex assays promise to revolutionize oncology research and
drug development. The progress made since the early access program was
initiated in early November 2018 with select industry leaders has
validated the performance and promise of the technology, resulting in an
accelerated timeline for full launch. The company is now taking orders
for shipping by April 1.

For the first time, researchers are able to access over one thousand
assay configurations of critical immunomodulatory biomarkers for
oncology research with multiplexing up to 10-plex without sacrificing
sensitivity. The broad assay menu covers more than 50 analytes and
enables researchers to easily develop custom homebrew assays, further
extending the range of applications to include PK/PD and immunogenicity
assays as well. Simoa CorPlex assays undergo extensive validation,
providing one of the most highly validated assay menus in the industry,
ensuring customers can utilize the assays in the most demanding clinical
and translational research applications. The next generation Simoa
planar array technology utilized in CorPlex assays promotes non-invasive
biomarker measurements, supporting easier and more approachable methods
for determining drug efficacy and toxicity. This addresses the
previously unmet needs of oncology researchers, particularly in the
rapidly expanding fields of immuno-oncology and immunotherapy, including
checkpoint inhibitors and CAR-T cell therapies.

“Immuno-oncology-based treatments have long shown tremendous promise for
improving how we treat cancers, but researchers have lacked reliable
methods to test the efficacy and toxicity of those treatments early in
therapeutic intervention,” said Kevin Hrusovsky, Chief Executive
Officer, President and Chairman of Quanterix. “The ability to monitor
the interaction of the patient immune system and tumor biology by
measuring multiple analytes simultaneously is critical but has not been
possible with sufficient sensitivity until now. The SP-X instrument with
CorPlex assays mark the latest addition to our ultra-sensitive product
portfolio, supplying researchers with the tools they need to determine
whether immunotherapies are having the desired effect at the earliest
stages of the disease, saving resources and, ultimately, lives.”

While immunotherapies have gained traction as a promising way to treat
many cancers, the inability to optimize dosing and the occurrence of
immune-related adverse events have hindered progress. Critical
biomarkers that would enable researchers to make informed decisions with
respect to dosing and toxicities are often at such low concentrations
that the reliable measurement has been problematic until now. With Simoa
CorPlex assays, researchers can measure concentrations of key
circulating cytokines and immunological biomarkers across all stages of
disease progression including normal healthy baseline levels. This means
that researchers will be able to more quickly see whether the
immunotherapy or other cancer treatments are working, or potentially
avoid severe side effects such as neurotoxicity and cytokine release
syndrome. This means the Simoa CorPlex could have the potential to
catalyze dramatic reductions in treatments costs, which can amount to
several hundred thousand dollars a year.

General availability of Simoa CorPlex is made possible by the SP-X
Imaging and Detection System
, Quanterix’ new state-of-the-art
benchtop imager that utilizes a proprietary planar array technology,
offering advanced multiplexing capabilities with the same Simoa
sensitivity found in the company’s HD-1 and SR-X instruments. Building
on the success of Quanterix’ flagship Simoa technology, the SP-X and
Simoa CorPlex are meeting the needs of oncology researchers with the
goal of revolutionizing patient care.

About Quanterix
Quanterix is a company that’s digitizing
biomarker analysis with the goal of advancing the science of precision
health. The company’s digital health solution, Simoa, has the potential
to change the way in which healthcare is provided today by giving
researchers the ability to closely examine the continuum from health to
disease. Quanterix’ technology is designed to enable much earlier
disease detection, better prognoses and enhanced treatment methods to
improve the quality of life and longevity of the population for
generations to come. The technology is currently being used for research
applications in several therapeutic areas, including oncology,
neurology, cardiology, inflammation and infectious disease. The company
was established in 2007 and is located in Lexington, Massachusetts. For
additional Information, please visit https://www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Words
such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,”
“intend” and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are intended to
identify forward-looking statements. Forward-looking statements in this
news release include statements relating to the promise of the SP-X and
Simoa CorPlex to revolutionize oncology research and drug development
and are based on Quanterix’ expectations and assumptions as of the date
of this press release. Each of these forward-looking statements involves
risks and uncertainties. Factors that may cause Quanterix’ actual
results to differ from those expressed or implied in the forward-looking
statements in this press release are discussed in Quanterix’ filings
with the U.S. Securities and Exchange Commission, including the “Risk
Factors” sections contained therein. Except as required by
law, Quanterix assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations, even
as new information becomes available.

Contacts

Lindsay Poole
PAN Communications
617-502-4300
quanterix@pancomm.com